GlassScriptPhysician profile
Robert G Finkel
NPI 1780769364
$1,678.11
in general payments reported to CMS, 2019-2025
18 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2021: $64.63 · 2022: $419 · 2023: $298 · 2024: $323 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $775.75 | 2019-2025 | |
| Celgene Corporation | $175.90 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.76 | 2019-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $102.56 | 2023-2025 | |
| Boston Scientific Corporation | $100.74 | 2022 | |
| Janssen Biotech, INC. | $93.98 | 2019-2024 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $57.72 | 2023-2024 | Ocaliva |
| Pfizer INC. | $44.17 | 2023-2025 | |
| Ardelyx, INC. | $40.04 | 2023 | Ibsrela |
| Daiichi Sankyo INC. | $29.75 | 2025 | Injectafer |
| Madrigal Pharmaceuticals | $23.36 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $20.77 | 2019 | |
| Gilead Sciences, INC. | $20.32 | 2023 | |
| Ferring Pharmaceuticals INC. | $19.39 | 2019 | |
| Allergan, INC. | $17.20 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.46 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.52 | 2019 | |
| Braintree Laboratories, INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Finkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.